POTELIGEO®▼(mogamulizumab) more than doubled median investigator-assessed progression-free survival (PFS) compared with vorinostat[1,a]

KAPLAN-MEIER CURVE FOR PFS[b] (N=372)



Abbreviations: CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.

Adapted from: POTELIGEO® Summary of Product Characteristics.[1]

POTELIGEO® is indicated in EU for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.[1]

For full prescribing information, refer to the Summary of Product Characteristics, available **here**

[a] Vorinostat is a USA FDA-licensed existing treatment for MF and SS and is currently unlicensed in the EU. All references to vorinostat within this document are included only for the purposes of accurately conveying details of the MAVORIC trial and are not intended to promote the use of vorinostat.

[b] Defined as the time from randomisation to a treatment arm until documented progressive disease or death due to any cause.[2]

1. POTELIGEO® Summary of Product Characteristics. Published: 28 January 2019. Last updated: 20 August 2021. Accessed: September 2021.
2. Kim YH, Bagot M, Pinter-Brown L, et al. *Lancet Oncol*. 2018;19(9):1192–1204.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email medinfo@kyowakirin.com

KKI/INT/MOG/0439 Date of preparation: October 2021.